Translational Psychiatry (Mar 2023)

Posttraumatic stress symptom severity predicts cognitive decline beyond the effect of Alzheimer’s disease biomarkers in Veterans

  • Sarah Prieto,
  • Kate E. Nolan,
  • Jena N. Moody,
  • Scott M. Hayes,
  • Jasmeet P. Hayes,
  • for the Department of Defense Alzheimer’s Disease Neuroimaging Initiative

DOI
https://doi.org/10.1038/s41398-023-02354-0
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 9

Abstract

Read online

Abstract Chronic stress is a risk factor for dementia but whether it explains unique variance in cognitive decline in older adults above Alzheimer’s disease (AD) biomarkers is unknown. In a preclinical cohort of Vietnam Veterans, we examined the relationship between posttraumatic stress disorder (PTSD) symptom severity, AD biomarkers of beta-amyloid (Aβ) and tau, and change in cognitive performance on two widely-used screeners, the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). Analyses indicated that PTSD symptom severity was associated with a greater decline on the MMSE (p < 0.04) and MoCA (p < 0.024) after adjusting for biomarkers of AD, notably on the attention scale of the MoCA and the memory index of the MMSE. These analyses survived multiple comparison corrections. Taken together, PTSD symptom severity is associated with accelerated cognitive decline. Treating PTSD should be considered instrumental to maintaining cognitive function as adults age.